Manchester Financial’s Achieve Life Sciences ACHV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$439K Buy
67,177
+955
+1% +$4.55K 0.08% 83
2026
Q1
$195K Buy
66,222
+7,138
+12% +$31.7K 0.04% 133
2025
Q4
$294K Buy
59,084
+12,410
+27% +$54.1K 0.05% 109
2025
Q3
$147K Buy
46,674
+450
+1% +$1.24K 0.03% 130
2025
Q2
$104K Buy
46,224
+22,000
+91% +$62.7K 0.02% 121
2025
Q1
$64.7K Buy
24,224
+4,594
+23% +$14.3K 0.01% 122
2024
Q4
$69.1K Hold
19,630
0.02% 113
2024
Q3
$93K Hold
19,630
0.02% 109
2024
Q2
$92.3K Buy
19,630
+530
+3% +$2.55K 0.02% 103
2024
Q1
$86.8K Hold
19,100
0.02% 95
2023
Q4
$78.7K Buy
19,100
+500
+3% +$2.18K 0.02% 92
2023
Q3
$80K Buy
18,600
+5,675
+44% +$28.6K 0.02% 91
2023
Q2
$67.1K Buy
+12,925
New +$90.6K 0.02% 96

Other funds holding ACHV

Manchester Financial's ACHV Position: Q2 2026 in Review

Manchester Financial increased its Achieve Life Sciences (ACHV) stake by 1.4% in Q2 2026, buying an estimated $4.55K and bringing the position to 67,177 shares worth $439K. The position accounts for 0.08% of the portfolio, ranked #83.

Manchester Financial first reported a position in ACHV in Q2 2023 and has held it in 13 quarters since. 8 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Manchester Financial held 67,177 shares of Achieve Life Sciences worth $439K as of Q2 2026.
  • Manchester Financial bought 955 Achieve Life Sciences shares in Q2 2026, an estimated $4.55K.
  • Achieve Life Sciences made up 0.08% of Manchester Financial's portfolio in Q2 2026, its #83 holding.
  • Manchester Financial first reported a position in Achieve Life Sciences in Q2 2023 and has held it in 13 quarters since.
  • 8 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Manchester Financial's 13F filing for Q2 2026, filed 17 Jul 2026.